Low-dose combination blood pressure pharmacotherapy to improve treatment effectiveness, safety, and efficiency

Mark D. Huffman*, Gbenga Ogedegbe, Marc Jaffe

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)552-554
Number of pages3
JournalJAMA - Journal of the American Medical Association
Volume320
Issue number6
DOIs
StatePublished - Aug 14 2018

Funding

completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Huffman reported receiving funding from the World Heart Federation to serve as its senior program advisor for the emerging leaders program, which is funded through unrestricted educational grants from Boehringer Ingelheim and Novartis with previous support from Bupa and AstraZeneca; funding support from the American Heart Association, Verily, and AstraZeneca; and being co-leader of a clinical trial evaluating the effects of quarter-dose, 4-drug blood pressure–lowering combination therapy, which is sponsored by the National Heart, Lung, and Blood Institute. No other disclosures were reported.

ASJC Scopus subject areas

  • General Medicine

Cite this